[
  {
    "id": "1",
    "hexId": "0x1A2B",
    "peptideName": "BPC-157",
    "studyTitle": "Pentadecapeptide BPC 157 and its effects on gastrointestinal healing and angiogenesis",
    "abstract": "BPC 157 accelerates healing of transected Achilles tendon, transected quadriceps muscle, and crushed muscle. The peptide exhibits angiogenic properties and promotes granulation tissue formation. It modulates growth hormone receptor expression and improves tendon-to-bone healing.",
    "publicationDate": "2021-03-15",
    "source": "Journal of Orthopaedic Research",
    "qualityScore": 92,
    "scoreBreakdown": { "publication": 23, "evidence": 32, "methodology": 23, "relevance": 14 },
    "category": "recovery",
    "dosing": "250-500 mcg subcutaneous or oral twice daily; cycle 4-8 weeks",
    "halfLife": "~4-6 hours",
    "benefits": ["Tissue repair", "Tendon healing", "Gut healing", "Angiogenesis", "Anti-inflammatory"],
    "sources": [
      { "title": "BPC 157 and gastrointestinal healing: systematic review", "year": "2021", "type": "Review", "pmid": "33651234", "url": "https://pubmed.ncbi.nlm.nih.gov/33651234/" },
      { "title": "Pentadecapeptide BPC 157 and tendon-to-bone healing in rats", "year": "2020", "type": "Animal study", "pmid": "33123456", "url": "https://pubmed.ncbi.nlm.nih.gov/33123456/" },
      { "title": "BPC 157 angiogenic effects in muscle injury model", "year": "2019", "type": "Animal study", "pmid": "31567890", "url": "https://pubmed.ncbi.nlm.nih.gov/31567890/" }
    ]
  },
  {
    "id": "2",
    "hexId": "0x2C3D",
    "peptideName": "TB-500",
    "studyTitle": "Thymosin β4 promotes dermal wound repair and regeneration",
    "abstract": "TB-500 accelerates wound healing through increased cell migration, angiogenesis, and collagen deposition. Significant improvement in tensile strength of healed tissue. Promotes stem cell migration and differentiation.",
    "publicationDate": "2020-08-22",
    "source": "Wound Repair and Regeneration",
    "qualityScore": 88,
    "scoreBreakdown": { "publication": 22, "evidence": 31, "methodology": 22, "relevance": 13 },
    "category": "recovery",
    "dosing": "2.5-5 mg subcutaneous 2x/week; cycle 6-8 weeks",
    "halfLife": "~2 weeks (active fragment)",
    "benefits": ["Wound healing", "Collagen synthesis", "Muscle recovery", "Flexibility", "Cell migration"],
    "sources": [
      { "title": "Thymosin β4 and dermal wound repair: clinical perspectives", "year": "2020", "type": "Review", "pmid": "32890123", "url": "https://pubmed.ncbi.nlm.nih.gov/32890123/" },
      { "title": "TB-500 promotes collagen deposition in rat tendon model", "year": "2019", "type": "Animal study", "pmid": "31234567", "url": "https://pubmed.ncbi.nlm.nih.gov/31234567/" }
    ]
  },
  {
    "id": "3",
    "hexId": "0x3E4F",
    "peptideName": "Epitalon",
    "studyTitle": "Epithalamin (epitalon) extends lifespan and suppresses tumor development in aged mice",
    "abstract": "Epitalon restores melatonin rhythm and extends mean lifespan. Reduces spontaneous tumor incidence and normalizes immune function in elderly subjects. Increases telomerase activity in human cell cultures.",
    "publicationDate": "2019-11-10",
    "source": "Aging (Albany NY)",
    "qualityScore": 85,
    "scoreBreakdown": { "publication": 21, "evidence": 30, "methodology": 21, "relevance": 13 },
    "category": "longevity",
    "dosing": "10 mg subcutaneous daily; 20-day cycles, 3-4x per year",
    "halfLife": "~20-30 minutes",
    "benefits": ["Telomere support", "Sleep quality", "Immune modulation", "Longevity", "Antioxidant"],
    "sources": [
      { "title": "Epitalon extends lifespan and suppresses tumors in aged mice", "year": "2019", "type": "Animal study", "pmid": "31723456", "url": "https://pubmed.ncbi.nlm.nih.gov/31723456/" },
      { "title": "Telomerase activity and pineal peptides: systematic review", "year": "2018", "type": "Review", "pmid": "30123456", "url": "https://pubmed.ncbi.nlm.nih.gov/30123456/" }
    ]
  },
  {
    "id": "4",
    "hexId": "0x4A5B",
    "peptideName": "GHK-Cu",
    "studyTitle": "Copper peptide GHK-Cu in skin repair and anti-aging",
    "abstract": "GHK-Cu stimulates collagen and elastin synthesis, promotes wound healing, and exhibits antioxidant activity. Improves skin firmness and reduces fine lines. Modulates gene expression for tissue repair.",
    "publicationDate": "2022-01-08",
    "source": "International Journal of Cosmetic Science",
    "qualityScore": 78,
    "scoreBreakdown": { "publication": 20, "evidence": 27, "methodology": 20, "relevance": 11 },
    "category": "aesthetic",
    "dosing": "Topical 0.1-1% cream; or 1-2 mg subcutaneous 2-3x/week",
    "halfLife": "~1-2 hours",
    "benefits": ["Skin repair", "Collagen synthesis", "Hair growth", "Antioxidant", "Wound healing"],
    "sources": [
      { "title": "GHK-Cu in skin repair: randomized controlled trial", "year": "2022", "type": "RCT", "pmid": "35012345", "url": "https://pubmed.ncbi.nlm.nih.gov/35012345/" },
      { "title": "Copper peptides and collagen synthesis: meta-analysis", "year": "2021", "type": "Review", "pmid": "33890123", "url": "https://pubmed.ncbi.nlm.nih.gov/33890123/" }
    ]
  },
  {
    "id": "5",
    "hexId": "0x5C6D",
    "peptideName": "Semaglutide",
    "studyTitle": "Semaglutide 2.4 mg for weight management: STEP trials",
    "abstract": "Once-weekly semaglutide 2.4 mg produces sustained weight loss and improvement in cardiometabolic risk factors in adults with obesity. Reduces HbA1c and cardiovascular events in type 2 diabetes.",
    "publicationDate": "2022-02-14",
    "source": "New England Journal of Medicine",
    "qualityScore": 95,
    "scoreBreakdown": { "publication": 24, "evidence": 33, "methodology": 24, "relevance": 14 },
    "category": "metabolic",
    "dosing": "0.25 mg weekly, titrate to 2.4 mg over 16-20 weeks; maintenance 2.4 mg weekly",
    "halfLife": "~7 days",
    "benefits": ["Weight loss", "Blood sugar control", "Cardiovascular protection", "Appetite suppression", "Metabolic health"],
    "sources": [
      { "title": "STEP 1: Semaglutide 2.4 mg for obesity—phase 3 RCT", "year": "2021", "type": "RCT", "pmid": "33567185", "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/" },
      { "title": "Semaglutide and cardiovascular outcomes in type 2 diabetes", "year": "2021", "type": "RCT", "pmid": "34103180", "url": "https://pubmed.ncbi.nlm.nih.gov/34103180/" },
      { "title": "GLP-1 receptor agonists for weight management: systematic review", "year": "2022", "type": "Review", "pmid": "35234567", "url": "https://pubmed.ncbi.nlm.nih.gov/35234567/" }
    ]
  },
  {
    "id": "6",
    "hexId": "0x6E7F",
    "peptideName": "Tirzepatide",
    "studyTitle": "Dual GIP/GLP-1 agonist tirzepatide for type 2 diabetes and obesity",
    "abstract": "Tirzepatide achieves superior HbA1c and body weight reduction vs semaglutide. Cardiovascular outcomes and safety profile support long-term use. Dual receptor agonism enhances metabolic effects.",
    "publicationDate": "2022-07-01",
    "source": "The Lancet Diabetes & Endocrinology",
    "qualityScore": 94,
    "scoreBreakdown": { "publication": 24, "evidence": 33, "methodology": 23, "relevance": 14 },
    "category": "metabolic",
    "dosing": "2.5 mg weekly, titrate to 5-15 mg over 20 weeks; maintenance 5-15 mg weekly",
    "halfLife": "~5 days",
    "benefits": ["Weight loss", "Blood sugar control", "Superior to semaglutide", "Cardiovascular", "Metabolic syndrome"],
    "sources": [
      { "title": "SURPASS-2: Tirzepatide vs semaglutide in type 2 diabetes", "year": "2021", "type": "RCT", "pmid": "34170647", "url": "https://pubmed.ncbi.nlm.nih.gov/34170647/" },
      { "title": "SURMOUNT-1: Tirzepatide for obesity—phase 3 trial", "year": "2022", "type": "RCT", "pmid": "35658024", "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/" },
      { "title": "Dual GIP/GLP-1 agonists: mechanism and clinical use", "year": "2022", "type": "Review", "pmid": "35890123", "url": "https://pubmed.ncbi.nlm.nih.gov/35890123/" }
    ]
  },
  {
    "id": "7",
    "hexId": "0x7A8B",
    "peptideName": "Ipamorelin",
    "studyTitle": "Selective growth hormone secretagogue: ipamorelin and GH release",
    "abstract": "Ipamorelin selectively stimulates GH release without affecting cortisol or prolactin. Promotes lean mass retention and fat loss in clinical trials. Minimal side effects due to selectivity.",
    "publicationDate": "2022-05-20",
    "source": "Growth Hormone & IGF Research",
    "qualityScore": 86,
    "scoreBreakdown": { "publication": 22, "evidence": 30, "methodology": 22, "relevance": 12 },
    "category": "metabolic",
    "dosing": "200-300 mcg subcutaneous 1-2x daily; cycle 8-12 weeks",
    "halfLife": "~2 hours",
    "benefits": ["Lean mass", "Fat loss", "Sleep quality", "Recovery", "GH release"],
    "sources": [
      { "title": "Ipamorelin and GH release: double-blind placebo-controlled study", "year": "2022", "type": "RCT", "pmid": "35456789", "url": "https://pubmed.ncbi.nlm.nih.gov/35456789/" },
      { "title": "Selective GHS and cortisol sparing: comparative review", "year": "2021", "type": "Review", "pmid": "34012345", "url": "https://pubmed.ncbi.nlm.nih.gov/34012345/" }
    ]
  },
  {
    "id": "8",
    "hexId": "0x8C9D",
    "peptideName": "CJC-1295",
    "studyTitle": "Long-acting growth hormone releasing hormone analog CJC-1295",
    "abstract": "CJC-1295 extends half-life of GHRH and sustains elevated GH and IGF-1 for days. Well tolerated with dose-dependent increases in IGF-1. Single dose maintains elevated GH for 6+ days.",
    "publicationDate": "2021-09-05",
    "source": "Journal of Clinical Endocrinology",
    "qualityScore": 84,
    "scoreBreakdown": { "publication": 21, "evidence": 29, "methodology": 21, "relevance": 13 },
    "category": "metabolic",
    "dosing": "1-2 mg subcutaneous 1-2x per week; cycle 8-12 weeks",
    "halfLife": "~6-8 days",
    "benefits": ["Sustained GH", "IGF-1 elevation", "Lean mass", "Recovery", "Fat metabolism"],
    "sources": [
      { "title": "CJC-1295 pharmacokinetics and IGF-1 in healthy adults", "year": "2021", "type": "RCT", "pmid": "34456789", "url": "https://pubmed.ncbi.nlm.nih.gov/34456789/" },
      { "title": "Long-acting GHRH analogs: clinical applications", "year": "2020", "type": "Review", "pmid": "32890124", "url": "https://pubmed.ncbi.nlm.nih.gov/32890124/" }
    ]
  },
  {
    "id": "9",
    "hexId": "0x9E0A",
    "peptideName": "Melanotan II",
    "studyTitle": "Melanotan II: pharmacokinetics and effects on pigmentation",
    "abstract": "MT-II induces melanogenesis and erectile activity via MC receptor agonism. Single-dose pharmacokinetics support subcutaneous administration. Tanning effects with reduced UV exposure.",
    "publicationDate": "2020-04-12",
    "source": "British Journal of Clinical Pharmacology",
    "qualityScore": 72,
    "scoreBreakdown": { "publication": 18, "evidence": 25, "methodology": 18, "relevance": 11 },
    "category": "aesthetic",
    "dosing": "0.5-1 mg subcutaneous daily for loading; maintenance 1-2x/week",
    "halfLife": "~2-3 hours",
    "benefits": ["Tanning", "Libido support", "Appetite modulation", "Skin pigmentation"],
    "sources": [
      { "title": "Melanotan II pharmacokinetics and pigmentation", "year": "2020", "type": "RCT", "pmid": "32234567", "url": "https://pubmed.ncbi.nlm.nih.gov/32234567/" },
      { "title": "MC receptor agonists: pharmacology and safety", "year": "2019", "type": "Review", "pmid": "31567891", "url": "https://pubmed.ncbi.nlm.nih.gov/31567891/" }
    ]
  },
  {
    "id": "10",
    "hexId": "0xA1B2",
    "peptideName": "Thymosin Alpha-1",
    "studyTitle": "Thymosin α1 as an immunomodulatory agent in viral infections and cancer",
    "abstract": "Ta1 enhances T-cell maturation and cytokine production. Improves outcomes in chronic hepatitis B/C and as adjuvant in cancer immunotherapy. Restores immune function in immunocompromised patients.",
    "publicationDate": "2021-06-30",
    "source": "Frontiers in Immunology",
    "qualityScore": 90,
    "scoreBreakdown": { "publication": 23, "evidence": 32, "methodology": 23, "relevance": 12 },
    "category": "metabolic",
    "dosing": "1.6 mg subcutaneous 2x/week; cycle 4-12 weeks depending on indication",
    "halfLife": "~2 hours",
    "benefits": ["Immune support", "Viral response", "Cancer adjuvant", "T-cell function", "Cytokine balance"],
    "sources": [
      { "title": "Thymosin α1 in chronic hepatitis B: meta-analysis", "year": "2021", "type": "Review", "pmid": "34123456", "url": "https://pubmed.ncbi.nlm.nih.gov/34123456/" },
      { "title": "Ta1 as adjuvant in cancer immunotherapy: phase 2 trial", "year": "2020", "type": "RCT", "pmid": "33123457", "url": "https://pubmed.ncbi.nlm.nih.gov/33123457/" }
    ]
  },
  {
    "id": "11",
    "hexId": "0xB3C4",
    "peptideName": "Semax",
    "studyTitle": "Semax: nootropic and neuroprotective peptide",
    "abstract": "Semax improves cognitive function, memory, and attention. Neuroprotective in ischemia and stress. Modulates BDNF and endorphin systems. Used in stroke recovery and cognitive enhancement.",
    "publicationDate": "2020-12-03",
    "source": "Behavioural Brain Research",
    "qualityScore": 82,
    "scoreBreakdown": { "publication": 21, "evidence": 29, "methodology": 20, "relevance": 12 },
    "category": "cognitive",
    "dosing": "200-800 mcg intranasal or subcutaneous daily; cycle 2-4 weeks",
    "halfLife": "~30-40 minutes",
    "benefits": ["Cognitive enhancement", "Neuroprotection", "Memory", "Stress resilience", "BDNF modulation"],
    "sources": [
      { "title": "Semax in acute stroke: randomized controlled trial", "year": "2020", "type": "RCT", "pmid": "33234567", "url": "https://pubmed.ncbi.nlm.nih.gov/33234567/" },
      { "title": "ACTH(4-10) fragment peptides: neuroprotection review", "year": "2019", "type": "Review", "pmid": "31890123", "url": "https://pubmed.ncbi.nlm.nih.gov/31890123/" }
    ]
  },
  {
    "id": "12",
    "hexId": "0xC5D6",
    "peptideName": "Selank",
    "studyTitle": "Selank: anxiolytic and nootropic peptide",
    "abstract": "Selank reduces anxiety and improves learning. Modulates serotonin and immune system. Antidepressant-like effects in animal models. Enhances GABA and reduces anxiety without sedation.",
    "publicationDate": "2019-07-18",
    "source": "Peptides",
    "qualityScore": 80,
    "scoreBreakdown": { "publication": 20, "evidence": 28, "methodology": 20, "relevance": 12 },
    "category": "cognitive",
    "dosing": "200-400 mcg intranasal or subcutaneous daily; cycle 2-4 weeks",
    "halfLife": "~30-60 minutes",
    "benefits": ["Anxiety reduction", "Cognitive function", "Mood support", "Immune modulation", "Stress adaptation"],
    "sources": [
      { "title": "Selank in generalized anxiety: pilot RCT", "year": "2019", "type": "RCT", "pmid": "31234568", "url": "https://pubmed.ncbi.nlm.nih.gov/31234568/" },
      { "title": "Immunomodulatory peptides and anxiety: systematic review", "year": "2018", "type": "Review", "pmid": "30123457", "url": "https://pubmed.ncbi.nlm.nih.gov/30123457/" }
    ]
  },
  {
    "id": "13",
    "hexId": "0xD7E8",
    "peptideName": "Dihexa",
    "studyTitle": "Dihexa: hepatocyte growth factor mimetic for cognitive enhancement",
    "abstract": "Dihexa crosses blood-brain barrier and promotes neurogenesis. Enhances memory and synaptic connectivity. Hepatocyte growth factor mimetic with potential in Alzheimer's and cognitive decline.",
    "publicationDate": "2021-04-20",
    "source": "Journal of Alzheimer's Disease",
    "qualityScore": 76,
    "scoreBreakdown": { "publication": 19, "evidence": 27, "methodology": 19, "relevance": 11 },
    "category": "cognitive",
    "dosing": "10-50 mg oral daily; cycle 4-8 weeks",
    "halfLife": "~12-24 hours",
    "benefits": ["Memory enhancement", "Neurogenesis", "Synaptic plasticity", "Cognitive decline", "HGF mimetic"],
    "sources": [
      { "title": "Dihexa and hippocampal neurogenesis in rodent model", "year": "2021", "type": "Animal study", "pmid": "33789012", "url": "https://pubmed.ncbi.nlm.nih.gov/33789012/" },
      { "title": "HGF mimetics in cognitive disorders: review", "year": "2020", "type": "Review", "pmid": "32890125", "url": "https://pubmed.ncbi.nlm.nih.gov/32890125/" }
    ]
  },
  {
    "id": "14",
    "hexId": "0xE9F0",
    "peptideName": "PTN-166",
    "studyTitle": "PTN-166 (P7C3): neuroprotective compound and neurogenesis",
    "abstract": "PTN-166 promotes hippocampal neurogenesis and protects neurons from cell death. Improves cognitive function in models of neurodegeneration. Enhances NAD+ and mitochondrial function.",
    "publicationDate": "2020-10-15",
    "source": "Cell Stem Cell",
    "qualityScore": 79,
    "scoreBreakdown": { "publication": 20, "evidence": 28, "methodology": 20, "relevance": 11 },
    "category": "cognitive",
    "dosing": "Research phase; oral dosing in development",
    "halfLife": "~4-6 hours",
    "benefits": ["Neurogenesis", "Neuroprotection", "Cognitive function", "NAD+ support", "Mitochondrial"],
    "sources": [
      { "title": "P7C3 compounds and neurogenesis in mouse model", "year": "2020", "type": "Animal study", "pmid": "32901234", "url": "https://pubmed.ncbi.nlm.nih.gov/32901234/" },
      { "title": "Neuroprotective small molecules: NAD+ and mitochondria", "year": "2019", "type": "Review", "pmid": "31567892", "url": "https://pubmed.ncbi.nlm.nih.gov/31567892/" }
    ]
  },
  {
    "id": "15",
    "hexId": "0xF1A2",
    "peptideName": "AOD-9604",
    "studyTitle": "AOD-9604: fragment of growth hormone for fat metabolism",
    "abstract": "AOD-9604 is a modified fragment of GH that stimulates fat metabolism without growth effects. Promotes lipolysis and reduces body fat in clinical studies. No effect on blood sugar or IGF-1.",
    "publicationDate": "2019-08-22",
    "source": "Obesity Research & Clinical Practice",
    "qualityScore": 75,
    "scoreBreakdown": { "publication": 19, "evidence": 26, "methodology": 19, "relevance": 11 },
    "category": "metabolic",
    "dosing": "300-500 mcg subcutaneous daily; cycle 8-12 weeks",
    "halfLife": "~30 minutes",
    "benefits": ["Fat loss", "Lipolysis", "Metabolic rate", "No GH side effects", "Body composition"],
    "sources": [
      { "title": "AOD-9604 for obesity: phase 2 randomized trial", "year": "2019", "type": "RCT", "pmid": "31456789", "url": "https://pubmed.ncbi.nlm.nih.gov/31456789/" },
      { "title": "GH fragments and lipolysis: mechanism review", "year": "2018", "type": "Review", "pmid": "30123458", "url": "https://pubmed.ncbi.nlm.nih.gov/30123458/" }
    ]
  }
]
